North America HIV Injection Market, By Drug Type, By Distribution Channel, By Country - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

REPORT HIGHLIGHT

North American HIV Injection Market size was valued at USD 400.90 million in 2023, expanding at a CAGR of 14.09% from 2024 to 2032.

Antiretroviral injectables represent the latest advancement in antiretroviral therapy for individuals living with HIV. These extended-release medications offer a convenient alternative to daily oral medication. Recently, the U.S. Food and Drug Administration has given the green light to Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) against sexually acquired HIV. In regions like North America and Australia, Cabenuva combines cabotegravir and rilpivirine under one brand name, allowing for dosing once a month or every two months.

North America HIV Injection Market- Market Dynamics

The significant prevalence of HIV is expected to result in a high demand for medications, particularly injectable therapies, which will likely fuel market growth.

North America is a significant market for HIV injections due to its advanced healthcare infrastructure and high prevalence rates in certain demographics. The availability of advanced treatment options and healthcare access further drives growth in this market segment. Notable gains have been made in increasing PrEP use for HIV prevention in the U.S., with about 25% of the 1.2 million people recommended for PrEP being prescribed it in 2020, according to the U.S. Centers for Disease Control and Prevention. Supportive government policies and initiatives aimed at combating HIV/AIDS, including funding for research, treatment programs, and awareness campaigns, present growth opportunities for the market. However, stringent regulatory requirements may hinder market growth.

North America HIV Injection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 14.09% over the forecast period (2024-2032)

Based on countries, the U.S. was the leading revenue generator in 2023

North America HIV Injection Market- Segmentation Analysis:

The North American HIV Injection Market is segmented based on Drug Type, Distribution Channel, and Country.

The market has been segmented into four divisions according to Drug Type: Antiretroviral therapy (ART), Pre-exposure Prophylaxis (PrEP), and Long-acting Injectables. In North America, the HIV injection market displays favorable growth prospects in ART, PrEP, and Long-acting Injectables, propelled by improvements in treatment effectiveness, patient compliance, and the expansion of preventive strategies.

The market is segmented into three categories according to Distribution channels: Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. The dominant category is others, which encompasses online pharmacies, community health centers, and NGOs, and is increasingly dominating the distribution channel for HIV injections.

North America HIV Injection Market- Geographical Insights

The examination of the HIV Injection market in North America encompasses countries like the United States and Canada. The United States dominates the market share, attributed to the growing number of diagnoses and treatments, as well as the utilization of advanced therapies. With one of the highest rates of HIV/AIDS incidence in North America, the United States experiences a significant need for efficient treatment choices, particularly injectable therapies.

North America HIV Injection Market- Competitive Landscape:

The competitive landscape of the HIV injection market in North America is marked by fierce competition among pharmaceutical companies, spurred by the need for efficient treatments and preventive measures. Key players compete through innovation, pricing strategies, market accessibility, and patient involvement. These companies strive to launch new formulations like long-acting injectables to improve patient compliance and treatment results. Sustained innovation, strategic collaborations, and successful market access plans are crucial for sustaining a competitive edge and addressing the changing requirements of patients and healthcare professionals in the area.

Recent Developments:

Merck, also known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has placed clinical holds on the investigational new drug applications (INDs) for the oral and implant formulations of islatravir (MK-8591) for HIV-1 pre-exposure prophylaxis (PrEP), the injectable formulation of islatravir for HIV-1 treatment and prevention, and the oral doravirine/islatravir (DOR/ISL) HIV-1 once-daily treatment.

Gilead Sciences, Inc. has revealed important data showcasing the extensive research pipeline of its groundbreaking HIV treatment. The recent findings delve into the clinical outcomes of a study examining a combination regimen of bictegravir and lenacapavir, as well as fresh discoveries from a survey of the combination of lenacapavir with broadly neutralizing antibodies (bNAbs). Additionally, new proof-of-concept data on GS-1720, a unique once-weekly integrase strand transfer inhibitor (INSTI), has been presented.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

NORTH AMERICA HIV INJECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Johnson & Johnson

Merck & Co.

Viatris Inc.

Theratechnologies Inc.

Genentech

Gilead Sciences

AbbVie Inc.

Others

NORTH AMERICA HIV INJECTION MARKET, BY DRUG TYPE - MARKET ANALYSIS, 2019 - 2032

Antiretroviral therapy (ART)

Pre-exposure Prophylaxis (PrEP)

Long-acting Injectables

NORTH AMERICA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacy

Drugs Stores & Retail Pharmacies

Others

NORTH AMERICA HIV INJECTION MARKET, BY COUNTRY- MARKET ANALYSIS, 2019 - 2032

North America

The U.S.

Canada